When BMS paid for the acquisition of Celgene in early January, investors who were not optimistic about the deal considered a big risk that Celgene’s blockbuster drug Revlimid faced a patent challenge and sales would shrink sharply. But a recent US Patent and Trademark Office (PTO) decision has given… Continue Reading The lenalidomide patent challenge threatens to be temporarily lifted! Dr. Reddy’s three patent challenges were invalidated
On June 17th, BMS announced at the EHA 2018 annual meeting that phase II ELOQUENT-3 study reached the primary endpoint, Empititi (elotuzumab) combined with poloximatil and low-dose dexamethasone (EPd regimen) compared to using pomametide alone And dexamethasone (Pd regimen) can significantly improve progression-free survival in patients with relapsed or refractory… Continue Reading Empliciti has significant benefits in the treatment of multiple myeloma with a 46% lower risk of disease progression
The data displayed by Mercury’s I-O star Keytruda on the ASCO 2018 is amazing, and almost everyone believes that Keytruda has no doubt seized the throne of lung immunotherapy. However, competitors do not seem to agree with this. In their view, the difference between their drug and Keytruda is very… Continue Reading What is the difference between the PD-1/PD-L1 drugs in Merck, BMS, and Roche?